US Q1 2020 EARNINGS SEASON IS NOT BAD, EXPECT NEGATIVE REVISIONS TO LINGER

Nearly 70% of the reporting season is out, while only 25% of companies have reported in Japan. As usual, US and EU, having more defensive sector mix, are more resilient vs. EMU during recessions. Japan isbehaving not too badly for the time being.

Highlights:

  • Two thirds of EU and US firms reported results. EU fared less well than the US. Beats are not so negative but yoy growth is -22% and -8%, respectively. The median stock result is better: -5% for EU and +1.7% for the US.
  • Q2 results will be much worse – bottom of the cycle in a base case scenario – but analysts expect growth in Q3 to remain lower vs Q1: there is still a long way to go for earnings’ downgrades.
  • Our earnings forecasts for 2020 and 2021 remain below consensus and have risks tilted on the downside.
  • Recovery uncertainties, a possible second wave of contagion, geopolitical frictions plus lack of unity in the euro area do not bode well for earnings revisions in the next months.
  • Concerning sector earnings growth (yoy), consumer services, pharma, staples, IT and utilities were better than discretionary, energy, financials and industrials. 
  • At the EM market level, the most export-oriented EM countries (Korean, Taiwan), which fared well through the COVID crisis, have disappointed the least. They have shown twice as high the ratio of positive to total surprises (65%) vs other EM markets covered (Brazil, China, India) but Q2 would be a more severe test.
  • Overall, we maintain an OW on equities, having reduced it significantly after the rally.
  • While market valuation looks stretched short term, we see positive total returns over one year, even incorporating huge earnings downside in 2020 and lower earnings recovery in 2021 compared to previous post-recession periods.

Download the full publication belo

US Q1 2020 EARNINGS SEASON IS NOT BAD, EXPECT NEGATIVE REVISIONS TO LINGER

RELATED INSIGHTS

COVID-19 FACTS & FIGURES
Pfizer and BioNTech candidate Covid-19 vaccine showed to be 95% effective in early analysis, an even better result compared to data released last week. Moderna candidate Covid-19 vaccine showed to be 94.5% effective in early trials involving 30,000 people. Switzerland announced ICU beds reached full capacity and no extra units are available. Oxford and AstraZeneca Covid-19 vaccine test results are expected by late December.
THE FED REMAINS SILENT ON CHANGES TO QE AND CALLS FOR FURTHER FISCAL STIMULUS
As widely expected, the November meeting was rather uneventful: chair Powell seized the opportunity to reiterate the strong forward guidance on rates illustrated in September and to reassure on the capability of unorthodox measures to cushion a possible downturn of the economy.
CHINA’S NEW “DUAL CIRCULATION STRATEGY”
At the end of October, China approved its “Dual Circulation Strategy” which is the new five-year economic plan (2021 – 2025). The concept has been under discussion for quite some time and President Xi highlighted it already in May. In a nutshell, the concept promotes domestic demand as the central growth engine. It foresees more independent and resilient supply chains while at the same time it intends to further opening-up the corporate sector and financial markets.